Paradigm Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Paradigm Asset Management's VRTX Position: Q2 2026 in Review
Paradigm Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 86% in Q2 2026, buying an estimated $133K and bringing the position to 650 shares worth $323K. The position accounts for 0.07% of the portfolio, ranked #234.
Paradigm Asset Management first reported a position in VRTX in Q1 2015 and has held it in 22 quarters since. The position peaked at $617K in Q2 2015. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Paradigm Asset Management held 650 shares of Vertex Pharmaceuticals worth $323K as of Q2 2026.
- Paradigm Asset Management bought 300 Vertex Pharmaceuticals shares in Q2 2026, an estimated $133K.
- Vertex Pharmaceuticals made up 0.07% of Paradigm Asset Management's portfolio in Q2 2026, its #234 holding.
- Paradigm Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 22 quarters since.
- Paradigm Asset Management's Vertex Pharmaceuticals position peaked at $617K in Q2 2015.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Paradigm Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.